- Home
- DAWN vs ADPT Comparison
DAWN vs ADPT Comparison
Compare DAWN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- ADPT
- Stock Information
- Founded
- DAWN 2018
- ADPT 2009
- Country
- DAWN United States
- ADPT United States
- Employees
- DAWN N/A
- ADPT N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DAWN Health Care
- ADPT Health Care
- Exchange
- DAWN Nasdaq
- ADPT Nasdaq
- Market Cap
- DAWN 1.2B
- ADPT 1.2B
- IPO Year
- DAWN 2021
- ADPT 2019
- Fundamental
- Price
- DAWN $12.43
- ADPT $8.27
- Analyst Decision
- DAWN Strong Buy
- ADPT Buy
- Analyst Count
- DAWN 7
- ADPT 5
- Target Price
- DAWN $36.17
- ADPT $9.10
- AVG Volume (30 Days)
- DAWN 782.5K
- ADPT 1.4M
- Earning Date
- DAWN 02-25-2025
- ADPT 02-11-2025
- Dividend Yield
- DAWN N/A
- ADPT N/A
- EPS Growth
- DAWN N/A
- ADPT N/A
- EPS
- DAWN N/A
- ADPT N/A
- Revenue
- DAWN $101,953,000.00
- ADPT $178,957,000.00
- Revenue This Year
- DAWN N/A
- ADPT $20.07
- Revenue Next Year
- DAWN $35.37
- ADPT $25.27
- P/E Ratio
- DAWN N/A
- ADPT N/A
- Revenue Growth
- DAWN N/A
- ADPT 5.10
- 52 Week Low
- DAWN $11.13
- ADPT $2.28
- 52 Week High
- DAWN $18.07
- ADPT $8.95
- Technical
- Relative Strength Index (RSI)
- DAWN 52.15
- ADPT 58.94
- Support Level
- DAWN $11.65
- ADPT $8.09
- Resistance Level
- DAWN $12.54
- ADPT $8.69
- Average True Range (ATR)
- DAWN 0.47
- ADPT 0.64
- MACD
- DAWN 0.02
- ADPT -0.00
- Stochastic Oscillator
- DAWN 80.53
- ADPT 65.66
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).